Why is it that some Indians who are exposed to the Human Immunodeficiency Virus (HIV) don’t get Acquired Immunodeficiency Syndrome (AIDS)? How do the anti-HIV and anti-tuberculosis drugs interact with each other inside patients who have both the diseases? What is the pattern of drug resistance in the HIV-positive population?
These are just three of the many crucial questions that Indian researchers might be able to answer by tapping into a centralised repository of serum samples that the government is building. The samples would be collected from AIDS patients, and from people who are at a high risk of contracting it.